A report discusses how Donald Trump's drug-pricing deals are reshaping large pharmaceutical companies, with implications for Pfizer, AbbVie, and Bristol Myers Squibb.
Finnhub07/14, 04:20 PM
Related assets
Coming up for PFE
Explore next
Latest PFE news
Jin1008/04, 08:22 PM
LiveSquawk08/04, 06:11 PM
ZeroHedge08/04, 05:45 PM
Pfizer raises full-year revenue guidance to $60.5B–$62.5B from prior $59.5B–$62.5B.